IO Biotech Q4 net loss $26.2M; Phase 3 melanoma trial enrollment complete, interim ORR analysis expected Q3 2024

IO Biotech, Inc.

Net loss $26.2M in Q4 2023 vs $20.1M YoY; R&D expenses $21.8M on Phase 3 trial costs.
Cash $143.2M at Dec 31, 2023; operational runway projected into Q4 2025.
Completed enrollment of 380 patients in pivotal Phase 3 trial of IO102-IO103 + Keytruda in advanced melanoma.
Planned interim ORR analysis from first 225 patients expected in Q3 2024; PFS primary endpoint anticipated H2 2025.
First patient dosed in Phase 2 basket trial of IO102-IO103 neoadjuvant/adjuvant in resectable solid tumors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IO Biotech, Inc. reported three months ended December 31, 2023 results: net income $26.2 million.

Period: three months ended December 31, 2023
Net income: $26.2 million
Result: reported results

Exact text from the filing

Net loss for the three months ended December 31, 2023, was $26.2 million, compared to $20.1 million for the three months ended December 31, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-059364

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.